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ABSTRACT 
Tepoxalin is a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory, and 
antipyretic properties and has been recently introduced into veterinary medicine. The aim 
of this study was to evaluate the pharmacokinetic/pharmacodynamic (PK/PD) profile of 
tepoxalin to assess whether it would be suitable for clinical use in horses. Six female 
fasting/fed horses were given 10 mg/kg tepoxalin orally in a cross-over study. After 
administration, tepoxalin underwent rapid and extensive hydrolytic conversion to its 
carboxylic acid metabolite RWJ-20142. In animals that had been fed, the plasma 
concentrations of tepoxalin were undetectable, whereas in fasting animals they were close 
to the limit of quantification of the method. No differences between the fasting/fed groups 
in RWJ-20142 plasma concentrations were shown. Tepoxalin showed a strong and long-
lasting ex vivo inhibitory activity against cyclooxygenase (COX)-1,  mainly due to its main 
metabolite RWJ-20142. Tepoxalin and RWJ-20142 do not seem to possess either COX-2 
or 5-lipoxygenase inhibitory activity in the horse. These features suggest that the drug is a 
selective COX-1 inhibitor in horses, with no significant anti-inflammatory activity. Thus, its 
long term use in equine practice could be of concern. 
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INTRODUCTION 
Chronic inflammatory diseases, such as osteoarthritis, are among the most common 
causes of reduced function in animals, especially horses (Richardson and Loinaz, 2007). 
Inflammation,pain, joint alteration/deformation, and impaired locomotion with variable (but 
usually worsening) degrees of incapacitation are common symptoms. The main aim of 
current therapeutic strategies is to alleviate the symptoms, particularly those of pain and 
inflammation. The most commonly used remedies are non-steroidal anti-inflammatory 
drugs (NSAIDs) (Goodrich and Nixon, 2006). However, NSAIDs can cause serious 
adverse effects, the most important of which are gastric lesions (e.g. ulceration), renal 
failure, and asthma (Lascelles et al., 2005). Both the adverse and therapeutic effects of 
NSAIDs are primarily the result of the inhibition of the activity of prostaglandin (PG) 
endoperoxide synthase, or cyclooxygenase (COX) (Brooks and Day,1991). Inhibition of 
the constitutively expressed COX-1 isoform causes gastric and intestinal mucosal damage 
and renal toxicity, 
whereas inhibition of the inflammatory-induced COX-2 isoform reduces inflammation. 
Arachidonic acid not metabolised to prostaglandins by the COX enzymes may enter into 
the lipoxygenase (LO) pathway, increasing the formation of leukotrienes (LTs) and 
cysteinyl-LT (Rainsford, 1987, 1993). This causes vasoconstriction at the level of gastric 
mucosa and increases the formation of reactive oxygen radicals from the peroxidative 
cleavage of hydroxyeicosatetraenoic acids (Los et al., 1995), resulting in further mucosal 
injury. The gastric and intestinal mucosal lesions produced by NSAIDs can be prevented 
by the concurrent administration of 5-LO inhibitors (Rainsford, 1987, 1993). 5-LO converts 
free arachidonic acid to the unstable intermediate 5-S-hydroperoxyeicosatetraenoic acid 
(5-HPETE), that is subsequently converted to LTA4, the 5,6 epoxide of arachidonic acid, 
which is also unstable (Goldyne, 1984; Stenson and Parker, 1984; Higgs and Moncada, 
1985). Depending on the constituent enzymes, LTA4 is then converted to a variety of LT 
derivatives, including LTB4 a potent chemotactic agent associated with inflammation that 
recruits, activates, and prolongs the actions of neutrophils and other inflammatory cells up-
regulating the cytokine production (Crooks and Stockley, 1998; Bertolini et al., 2001). 
Tepoxalin, 5(4-chlorophenyl)-N-hydroxy-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-
propanamide (Fig. 1), is a NSAID with analgesic, anti-inflammatory, and antipyretic 
properties that has recently been marketed for use in veterinary medicine. Tepoxalin has 
been approved for use in dogs by the European Committee for Medicinal Products for 
Veterinary Use (Zubrin, Schering-Plough) (Zubrin, EPARs/02/10/08). Due to its ability to 
inhibit both COX isoforms and 5-LO, it is considered a dual inhibitor (Wallace et al., 1993). 
By reducing the production of LTB4, tepoxalin might offer a novel approach to both the 
preservation of GI mucosal integrity and reduction of bronchoconstriction (Wallace et al., 
1993; Bertolini et al., 2001; Lees, 2009). Tepoxalin is supplied as a rapidly disintegrating 
tablet that completely dissolves within a few seconds in the animal’s mouth (Anonymous, 
2003). Studies conducted in rats (Knight et al., 1996), chickens (De Boever et al., 2009), 
rabbits (Pollock et al., 2008), dogs (Knight et al., 1996; Homer et al., 2005) and humans 
(Waldman et al., 1996) reported that the parent compound reached maximum plasma 
concentrations in a variable time (0.7–4 h), and was rapidly converted to the active 
metabolite RWJ-20142. The dual activity of tepoxalin and the potent COX-1 activity 
inhibition of its metabolite have been demonstrated in different studies (Argentieri et al., 
1994; Willburger et al., 1998; Goodman et al., 2009), and the long plasma half-life of the 
active metabolite allows once-a-day dosing (Homer et al., 2005). According to Waldman et 
al. (1996), only tepoxalin (and not RWJ-20142) contributes to 5-LO inhibition. However, 
Willburger et al. (1998) demonstrated that in human blood, although a low plasma 
concentration of tepoxalin can inhibit COX enzymes, the same concentration did not affect 
5-LO inhibition. Agnello et al. (2005) showed that in dogs administration of 10 mg/kg of 
tepoxalin once daily for 10 days significantly reduced PGE2 production but not LTB4. In 
the dog, tepoxalin has been shown to be effective and safe in its therapeutic range 
(Goodman et al., 2009) after single (Homer et al., 2005) and repeated (Knight et al., 1996) 
administrations. Tepoxalin has been experimentally used in chickens at high dosages (30 
mg/kg) with no adverse effects reported (De Boever et al., 2009). Several differences have 
been reported in pharmacokinetic (PK) parameters between species (Waldman et al., 
1996; Homer et al., 2005; Pollock et al., 2008; De Boever et al., 2009), so species-specific 
data are required. In the horse, there has been just one published study (Caruso et al., 
2009). This was a brief in vitro study which reported only the pharmacodynamic properties 
(PD) of tepoxalin, while data concerning the dynamics of RWJ-20142 were missing. In 
vitro analyses of PD need to be paired with PK data to predict the clinical response, as the 
latter influences the concentration of the active molecule within tissues. In fact COX 
selectivity generally decreases when in vivo assays are compared to in vitro results 
(Bertolini et al., 2001). This study was undertaken to assess whether tepoxalin has 
suitable clinical features in horses, by the evaluation of its PK/PD profile using an equine 
whole blood assay. 
 
MATERIALS AND METHODS 
 
The study protocol was approved by the Ethics Committee of the University of Pisa 
(authorization 9403) and transmitted to the Italian Ministry of Health. 
 
 
Animals and experimental design 
 
Six female horses, aged 7–12 years and weighing 450–550 kg, were used. The mares 
were considered clinically healthy on the basis of a physical examination and complete 
haematological analyses. Animals were randomly assigned to two treatment groups, using 
an open, single-dose, two treatment, two-period, cross-over design. Each subject received 
a single dose of 10 mg/kg tepoxalin using Zubrin 200 mg tablets (Schering-Plough), 
bought in an ordinary pharmacy. The first group (n = 3) received the treatment in the 
morning, after fasting for 12 h overnight up to 6 h after drug administration. The second 
group (n = 3) was treated in the morning 2 h after feeding. After a wash-out period of 2 
weeks the groups were reversed and the treatments repeated. Since no information was 
available for horses a long wash-out period was chosen. This not only guaranteed the 
absence of residual plasma concentrations of the drug and its metabolite, but also the lack 
of residual drug effect on clearance (induction/inhibition) (Toutain and Bousquet-Mélou, 
2004). The animals that were fed were provided with a diet composed of a mixture of 
ground cereals (Equifioc, Molitoria Val di Serchio) in the afternoon (1.5 kg/day) and alfalfa 
hay in the morning (8 kg/day). Fasting horses were given hay only 6 h after drug 
administration. All of the animals were given the oral lyophilised formulation dissolved in 
100 mL of distilled water via nasogastric tube. After administration, the nasogastric tube 
was rinsed with 1 L of distilled water to ensure complete delivery of the drug into the 
stomach. Objective symptoms such as sweating, excitement, trembling, and head nodding 
were scored using numerical rating scales (Derksen et al., 1999). Vital signs including 
blood pressure, heart rate, respiratory rate and body temperature were assessed during 
the study. A catheter was placed into the right jugular vein to facilitate blood sampling. 
Blood samples for PK analysis (10 mL) were collected at intervals of 0, 5, 15, 30, and 45 
min, and 1, 1.5, 2, 4, 6, 8, 10, 24, 34, 48, 58 and 72 h after tepoxalin administration, and 
placed in collection tubes containing lithium heparin. The blood samples were centrifuged 
at 400 g for 5 min within 30 min of collection, and the harvested plasma was stored at -20 
°C and was used within 14 days from collection. Blood samples for PD analysis were 
collected at 0, 2, 10, 24, 48 and 72 h after drug administration (n = 3). Blood for the COX-
1, COX-2 and 5-LO activities measurement was collected into siliconised glass, sodium-
heparinised and lithium-heparinised tubes (Venoject, Terumo), respectively. 
 
Preparation of samples for PD analysis 
 
Aliquots of non-heparinised blood (10 mL) were incubated at 37 °C for 1 h to allow 
thromboxane (TX)B2 production from platelets. Tubes were centrifuged at 400 g for 10 min 
at room temperature and the serum was stored at -20 °C. Aliquots (2 mL) of sodium-
heparinised blood were transferred into glass tubes containing a final concentration of 10 
lg/mL lipopolysaccharide (LPS) from Escherichia coli (serotype 0111:B4) (Sigma) in 
phosphate buffered saline (PBS) solution and incubated at 37 C for 24 h to simulate 
PGE2 production from mononuclear cells. Blood with PBS only was used as a negative 
control. At the end of the incubation period, blood was centrifuged at 400 g for 10 min at 
room temperature to obtain plasma. A 100 µL aliquot of plasma was mixed with 400 µL of 
HPLC-grade methanol (Carlo Erba) to precipitate proteins. The mixture was centrifuged at 
400 g for 10 min at room temperature; the supernatant was collected and stored at -20 °C. 
Aliquots (0.5 mL) of lithium-heparinised blood were transferred into glass tubes, containing 
60 µM calcium ionophore A23187 (Sigma) in DMSO, to stimulate LTB4 production from 
neutrophils. Blood with DMSO only was used as the negative control. Tubes were 
incubated at 37 °C for 30 min. Two millilitres of methanol were added to the mixture to 
precipitate proteins, and the tubes were immediately immersed in ice to stop the 
incubation. Tubes were centrifuged at 4000 g for 15 min at 4 °C and aliquots of the 
resulting supernatant were stored at 20 °C until used. TXB2, PGE2 and LTB4 were 
assayed using a commercial EIA kit (Assay Designs), in samples diluted 15-, 25- and 10-
fold, respectively, using the assay buffer supplied with the kit. 
 
Chromatographic assay 
 
High performance liquid chromatography (HPLC) was performed with a PU 980 isocratic 
pump (Jasco) attached to an AS-1550 autosampler (Jasco) and an 821-FP fluorimetric 
detector (Jasco). Integration was performed using Borwin chromatographic software 
(version 1.21). The compounds were separated on a C18 column (250 mm X 4.6 mm i.d., 
5 µm particles) (Gemini) with a mobile phase A, consisting of 0.01 M 1-octane-sulfonic 
acid (Sigma) in 0.01 M acetic acid (Sigma) in HPLCgrade water (Baker), and a mobile 
phase B consisting of tetrahydrofuran (Carlo Erba), mixed at 50/50 (v/v). The flow rate of 
the mobile phase was maintained at 1.0 mL/min. Injection volume was 50 µL and the 
detector wavelengths were set at 290 nm and 440 nm as excitation and emission, 
respectively (Giorgi et al., 2011). Briefly, the quantification of tepoxalin and RWJ-20142 in 
plasma samples was accomplished by chromatographic analysis of unknown samples in 
parallel with standard curve and quality control samples created using tepoxalin, RWJ-
20142 and RWJ-20294 (internal standard) pure standard powders (TopChem 
Laboratories). For each series of analyses, a standard curve was generated as well as 
nine quality control samples (three different concentrations) alongside the test samples. 
The limits of detection (LOD) and quantification (LOQ) were determined as analyte 
concentrations giving signal-to-noise ratios of 3 and 10, respectively. 
 
Preparation of samples for PK analysis 
 
The drug was extracted from horse plasma by the following procedure. The plasma 
sample (0.5 mL) was spiked with 10 µg/mL RWJ-20294 as an internal standard (100 µL) in 
a 2 mL plastic Eppendorf tube. The mixture was vortexed for 30 s and left to rest for 5 min. 
Acetonitrile (0.9 mL) (Carlo Erba) was added to the mixture as an extraction solvent. This 
mixture was vortexed, shaken for 10 min at 150 oscillation/min on a shaker, and then 
centrifuged at 5000 g at 4 °C for 15 min. Four hundred microlitres of the upper layer were 
transferred to a clean Eppendorf and centrifuged again for 15 min at 5000 g at 4 °C. Two 
hundred microlitres were separated in a 500 µL Eppendorf. The aqueous phase (50 µL) 
was then injected onto the HPLC system. 
 
PK evaluation 
 
The pharmacokinetic calculations were carried out using WinNonLin v 5.2.1 (Pharsight 
Corp). Maximum concentration (Cmax) of tepoxalin and RWJ-20142 in plasma, and the 
time required to reach Cmax (Tmax) were predicted from the data. The terminal rate 
constant (λ) was determined from the slope of the terminal phase of the plasma 
concentration curve that included a minimum of three points. The half-life of the terminal 
phase (T1/2λz) was calculated by the formula T1/2 = 0.693/λ. The area under the 
concentration/time curve (AUClast) was calculated using the linear trapezoidal rule. 
Changes in plasma concentrations of tepoxalin and RWJ-20142 were evaluated using the 
standard non-compartmental analysis, and the relative pharmacokinetic parameters were 
determined using standard non-compartmental equations (Gabrielsson and Weiner, 2002). 
 
Statistical analysis 
 
Normal distribution of data was assessed by the D’Agostino and Pearson omnibus 
normality test. Consequently, the differences between the pharmacokinetics of tepoxalin 
during the two periods of administration, as well as the effect on prostanoid levels and 
percentage inhibition of prostanoid production were calculated using a repeat measures 
ANOVA, followed by the Newman–Keuls multiple comparison test. The effect of 
fasting/feeding status on the results was assessed using the twoway ANOVA with the 
Bonferroni correction as a post hoc test. A cut-off value of 20% inhibition of COX-1 was 
taken as the percentage value above which there may be a risk of adverse effects, and a 
cut-off value of 80% inhibition of both COX-2 and 5-LO was taken as the percentage value 
above which a good therapeutic effect would be expected (Giraudel et al., 2005). The 
results are reported as mean values (±SEM). All the analyses were conducted using 
GraphPad InStat v.4.0 (GraphPad Software). In all the experiments, differences were 
considered significant if the associated P value was <0.05. 
 
RESULTS 
 
Throughout the study no abnormality ascribable to the drug under study was observed as 
assessed by the measurement of objective symptoms, vital signs, physical examination 
and laboratory analysis. 
 
PK analysis 
 
The analytical method had a LOQ of tepoxalin and RWJ-20142 of 25 ng/mL and 20 ng/mL, 
respectively. The maximum value of the CV in intra-/inter-day assay precision for tepoxalin 
and metabolite was 5.5%. The plasma concentration vs. time curves for tepoxalin and 
RWJ-20142 were best fitted to a non-compartmental model. In fasting animals, the plasma 
profile of tepoxalin showed lower concentrations (Fig. 2). The Cmax (96.8 ± 55.0 ng/mL) 
was reached in a short time (Tmax 1.5 ± 0.2 h) and the drug rapidly disappeared from the 
blood compartment (T1/2 λz 2.78 ± 0.99 h) (Table 1). One of the six horses had all plasma 
concentrations below the LOQ, and another had only two collection points that were above 
this level. A wide variation in plasma concentrations among the subjects was observed. 
The metabolite RWJ-20142 showed a higher Cmax (1250 ± 187.4 ng/mL), a longer Tmax 
(9.6 ± 0.4 h) and a longer T1/2 λz (6.3 ± 0.1 h), than the parental compound. In the plasma 
of fed animals, tepoxalin concentration did not exceed the LOQ of 25 ng/mL in any horse 
at any time point. In this experimental group, the T1/2 λz of RWJ-20142 was significantly 
(P = 0.03) higher (8.8 ± 1.0 h) than in fasting animals (6.3 ± 0.1 h), but the 
pharmacokinetic profile of RWJ-20142 (Fig. 2) and the other parameters were not 
significantly different between the two groups (Table 1). In both treatments, RWJ-20142 
showed a biphasic mode of formation: a first rapid phase (1.5–2 h), and a second slower 
phase culminating with the Tmax (7.7 h fed group; 9.6 h fasting group). The single curves 
calculated for each animal showed the same trend (data not shown). The end of the first 
phase coincided with the Tmax of the parental drug in fasting horses. 
 
PD analysis 
 
In fasting and fed horses, induced TXB2 concentrations were 256.3 ± 117.5 ng/mL and 
83.9 ± 22.1 ng/mL, respectively; background PGE2 concentrations were 0.4 ± 0.1 ng/mL 
and 0.7 ± 0.2 ng/mL, respectively; induced PGE2 concentrations were 0.7 ± 0.1 ng/mL and 
2.4 ± 0.4 ng/mL, respectively; background LTB4 concentrations were 0.1 ± 0.0 ng/mL and 
0.1 ± 0.0 ng/mL, respectively; induced LTB4 concentrations were 3.6 ± 0.3 ng/mL and 3.1 
± 0.6 ng/mL, respectively. Administration of tepoxalin at 10 mg/kg significantly decreased 
TXB2 concentrations at all experimental time points in both fasting (0 h vs. 48 h, P < 0.05 
and 0 h vs. all other times, P < 0.01) and fed (P < 0.001) horses compared with the basal 
values. The maximal inhibition of serum TXB2 occurred at 24 h and was maintained for up 
to 72 h after administration (Figs. 3a and 4a). At this time point, serum TXB2 activity was 
still inhibited by 90.4 ± 4.3% and 85.8 ± 1.1% in fasting and fed animals, respectively 
(Table 2). Although a reduction in concentrations of PGE2 was found, this parameter did 
not decrease significantly within 48 h of drug administration (P > 0.05). It reached its 
maximal inhibition at 10 h (Table 2), both in fasting and fed horses. The inhibition time 
corresponded to the Cmax of RWJ-20142. PGE2 levels reverted back to the stimulated 
basal values within 72 h of tepoxalin administration, (Figs. 3b and 4b). The concentration 
of LTB4 was significantly increased by stimulation with calcium ionophore (P < 0.001 and 
P < 0.01 in fasting and fed animals, respectively). In both fasting and fed horses, tepoxalin 
decreased LTB4 concentrations 2 h after administration, along with the Cmax of tepoxalin, 
even if the values were not statistically significant (P > 0.05). At all other times, LTB4 
concentrations were similar to the stimulated basal values (Figs. 3c and 4c). Maximum 
inhibition of COX-1 (99.7 ± 0.1% and 99.6 ± 0.1% in fasting and fed horses, respectively) 
exceeded the cut-off value of 20%, whereas the maximum percentage inhibition of both 
COX-2 (68.9 ± 26.6% and 65.1 ± 8.0% in fasting and fed horses, respectively) and 5-LO 
(37.5 ± 2.9% and 43.4 ± 4.7% in fasting and fed horses, respectively) did not exceed the 
cut-off value of 80% (Table 2). Fasting/feeding status significantly affected PGE2 
concentration, accounting for 29.43% of the total variance in PGE2 concentration (P = 
0.0002). In contrast, it only accounted for 2.93% and 0.83% of the total variance of TXB2 
and LTB4 values (P = 0.11 and P = 0.38, respectively) (Fig. 5a–c). 
 
DISCUSSION 
 
Several variations in PK/PD of NSAIDs among animal species have been reported (Lees 
et al., 2004a,b). Drugs with selective enzyme-inhibiting features in one species may have 
nonspecific activity in others. A PK/PD study in the target species is therefore essential for 
predicting the likely effectiveness and safety of the therapy. In this study PD analysis was 
carried out using whole blood assays, which tested TXB2 production during clotting, PGE2 
production during LPS stimulation and LTB4 production during calcium ionophore 
stimulation, as indices of the expression of platelet COX-1, monocyte COX-2 and 
neutrophil 5-LO activities, respectively. This method has the advantage of taking into 
account the clinically relevant target cells and the variable degree of protein binding of 
NSAIDs (Blain et al., 2002). In previous in vivo studies in other species, tepoxalin has 
been shown to undergo rapid and extensive conversion to its carboxylic acid hydrolysis 
product (RWJ-20142). In those studies, plasma concentrations of RWJ-20142 were found 
to be substantially higher and more persistent than those of the parental drug. The PK 
findings in this study were in line with those observed in the other species, although the 
low numbers of animals used mean that the robustness of the PK parameters determined 
for tepoxalin is limited and further studies in more animals are required to confirm our 
findings. In horses, the RWJ-20142/tepoxalin Cmax ratio was about 12, similar to rabbits 
(Pollock et al., 2008). Studies in dogs (Homer et al., 2005) and humans (Depré et al., 
1996; Waldman et al., 1996) reported values closer to five suggesting faster metabolism of 
tepoxalin in these species. When the AUC of RWJ-20142 obtained in this study was 
normalised to the orally administered dose of tepoxalin (2756 ng h/mg), the values 
obtained were similar to those of fasting dogs (2747 ng h/mg) (Homer et al., 2005), but 
higher than in chickens (1305 ng h/mg) (De Boever et al., 2009) and rabbits (1807 ng 
h/mg) (Pollock et al., 2008). This suggests that, if the same dose of the drug per kg 
bodyweight (BW) is administered, RWJ-20142 will have longer plasma persistence in 
horses and dogs than in chickens and rabbits. Induced TXB2 concentrations measured in 
the present study were significantly higher when compared to values reported by Brideau 
et al. (2001) (256.3 ± 117.5 ng/mL and 83.9 ± 22.1 ng/mL in fasting and fed horses, 
respectively, vs. 26 ± 12 ng/mL). The high concentration of vehicle (DMSO 0.4%) used in 
the in vitro experimental design performed by Brideau and co-workers may account for this 
difference. In fact, it is well known that DMSO possesses anti-inflammatory activity, by 
inhibiting platelet aggregation induced by arachidonic acid in a concentration-dependent 
manner (Santos et al., 2003). After drug exposure, the production of TXB2 by platelets 
was significantly suppressed, but the production of PGE2 and LTB4 by LPS- and calcium-
stimulated white blood cells, respectively, was not significantly altered. So our results 
suggest that an oral dose of 10 mg/kg of tepoxalin can inhibit COX-1 activity in the horse, 
but not COX-2 and 5-LO, consistent with a significantly different COX inhibition ratio than 
that reported in other species. However, the large inter-individual variation of in PGE2 
production, combined with the small number of animals (n = 3), may have resulted in a 
type II error (Warner, 2008). In the present study, inhibition of TXB2 production was 
detected for 2–72 h after drug administration, with peak inhibition reached between 2 and 
48 h. During this period of time, tepoxalin and its metabolite RWJ-20142 achieved maximal 
plasma levels, suggesting that both tepoxalin and its acid metabolite could be responsible 
for the COX-1 activity inhibition. The maximal inhibition of PGE2 occurred at 10 h 
contemporaneous with the Cmax of RWJ-20142, whereas that of LTB4 occurred at 2 h 
contemporaneously with the Cmax of tepoxalin. In the horse, the only previous report of 
the PD of tepoxalin in vitro (Caruso et al., 2009), confirmed its preferential inhibitory 
activity of COX-1 (IC50 = 0.0116 µM). In the same study, the inhibition of the COX-2 (IC50 
= 0.0752 µM) was higher than that of 5-LO (IC50 = 0.2233 µM), although in neither case 
was the inhibition significant. This finding of a preferential inhibition of COX-1 is consistent 
with the results of the present study (Table 2). However, in this study the inhibition of 5-LO 
tended to be higher than that of COX-2. This difference may be due to the in vivo 
metabolism of tepoxalin into its active metabolite RWJ-20142, which has a different PD 
profile from the parental compound. Comparing the maximum percentage of enzyme 
inhibitions with the cut-off values suggested by Giraudel et al. (2005), our results suggest 
that tepoxalin orally administered at a dose rate of 10 mg/kg would have weak anti-
inflammatory effects with a relatively high potential for adverse effects. Seventy-two hours 
after tepoxalin administration, COX-1 activity was still strongly inhibited, in both fasting and 
fed horses (90.37 ± 4.35% and 85.81 ± 1.12%, respectively), despite tepoxalin and RWJ-
20142 plasma concentrations both being under the LOQ. There was no such inhibition of 
COX-2 and 5-LO activities. The mechanism of a prolonged COX-1 activity inhibition for 
tepoxalin is not fully understood, but it could be related to its non-competitive mode of 
COX-1 inhibition, to the inhibition of COX-1 peroxidase (Munroe and Lau, 1995) or to 
possible covalent binding. Further investigation is required. It is unlikely, that tepoxalin acts 
like aspirin, (another non-competitive NSAID) as extensive dialysis of COX-1 enzyme after 
the drug administration can reverse the inhibitory effect of tepoxalin but not that of aspirin 
(Tam et al., 1995). In the dog, the influence of food has been reported to drastically 
increase both the bioavailability of tepoxalin and the production of RWJ-20142 (Homer et 
al., 2005). Diets that are rich in fats have been speculated to reduce the effect of the 
hepatic first-pass metabolism as a result of the preferential transport of the drug 
associated with lipoprotein into lymphatic vessels (Porter and Charman, 2001). In the 
horse, feeding a standard diet, which is low in fat, marginally influenced plasma 
concentrations of RWJ-20142. However the difference in T1/2kz between groups is likely 
to be of negligible clinical relevance. Our horses were fed a high fibre diet, which may 
affect tepoxalin pharmacokinetics (Pollock et al., 2008) and could be the cause of the 
difference in plasma concentration of tepoxalin between the experimental groups. Feeding 
also seems to have influenced the basal level of PGE2, with marked differences between 
fed and fasting horses. These variations are consistent with early studies highlighting the 
increase of PGE2 after corn supplementation (Cargile et al., 2004; Hall et al., 2004). In 
horses the peak plasma level of tepoxalin was significantly lower than in dogs (0.53–1.08 
lg/mL; Homer et al., 2005) and about half that in rabbits (0.21 µg/mL; Pollock et al., 2008), 
while the Cmax(s) of RWJ-20142 were consistent among all these species. Two different 
rate of metabolite formation were shown in both fed and fasted horses. The change in the 
slope of RWJ-20142 plasma concentration vs. time curves coincided with the beginning of 
the elimination phase of the parental drug. As soon as the parental drug concentration 
began to decrease, RWJ-20142 formation began to slowly increase. This could be due to 
rapid metabolism of tepoxalin in the gastrointestinal tract with subsequent absorption of 
the active metabolite and/or a higher rate of conversion of tepoxalin to RWJ-20142 than 
the rate of elimination, distribution and biotransformation of RWJ-20142. In the current 
study, as in chickens (De Boever et al., 2009), the presence of a time-dependent unknown 
peak was found in the chromatographic curves of plasma. It eluted between tepoxalin and 
the acid metabolite, in both fed and fasted horses. The unknown analyte represented 
approximately 10–15% in the peak area of the active metabolite and its maximal area was 
simultaneous with the Tmax of RWJ-20142 (10 h). This peak could potentially represent 
another active metabolite of tepoxalin. Further studies are needed to identify its molecular 
structure to further clarify the clinical effectiveness and safety of tepoxalin therapy. 
Conclusion In horses dosed orally with 10 mg /kg tepoxalin, the compound is present at 
very low levels in plasma because it is rapidly converted to its acid metabolite. At the 
tested dose rate, tepoxalin has both strong and long-lasting ex vivo inhibitory activity 
against COX-1. These effects seem mainly due to its main metabolite RWJ-20142. 
Tepoxalin and RWJ-20142 do not seem to possess either COX-2 or 5-LO inhibitory activity 
suggesting that, at a dose rate of 10 mg/kg BW, tepoxalin would have limited beneficial 
anti-inflammatory properties in horses, and that its long term use could be matter of 
concern. 
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FIGURES AND TABLES 
 
 
 
 
 
 
 
Fig. 1. Molecular structure of (a) tepoxalin, (b) its active acid metabolite (RWJ-20142) and 
(c) internal standard (RWJ-20294). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Observed mean concentrations of tepoxalin in fasting horses (N), and its active 
metabolite (RWJ-20142) in fasting (d) and fed horses (s), following single oral 
administration of 10 mg/kg tepoxalin (n = 6). Bars represent standard error of the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Mean ± SEM (n = 3) concentrations of thromboxane B2 (TXB2; a), prostaglandin 
E2 (PGE2; b) and leukotriene B4 (LTB4; c) vs. RWJ-20142 or tepoxalin plasma 
concentrations in fasting equine whole blood before and after single oral administration of 
tepoxalin (10 mg/kg). Within time intervals, repeated-measures one-way ANOVA found 
values significantly different for TXB2 (P < 0.01; P < 0.05) and for LTB4 (P < 0.001; P < 
0.01). K- = negative control; K+ = positive control. 
 
 
 
 
 
Fig. 4. Mean ± SEM (n = 3) concentrations of thromboxane B2 (TXB2; a), prostaglandin 
E2 (PGE2; b) vs. RWJ-20142 plasma concentrations, and leukotriene B4 (LTB4; c) in fed  
equine whole blood before and after single oral administration of tepoxalin (10 mg/kg). 
Within time intervals, repeated-measures one-way ANOVA found values significantly 
different for TXB2 (P < 0.001) and for LTB4 (P < 0.01; P < 0.05). K- = negative control; K+ 
= positive control. 
 
 
 
 
 
 
Fig. 5. Effect of feeding and fasting status on thromboxane B2 (TXB2; a), prostaglandin E2 
(PGE2; b) and leukotriene B4 (LTB4; c) production in equine whole blood (n = 3) before 
and after oral single administration of tepoxalin (10 mg/kg). No interactions were seen 
between TXB2 and LTB4 levels and the feeding/fasting status (P = not significant), 
whereas interactions were seen between PGE2 levels and the feeding/fasting status 
before tepoxalin administration (*P < 0.05). Statistical analysis: two-way ANOVA. 
 
 
 
 
 
  
 
 
Table 1 
Pharmacokinetic parameters of tepoxalin and RWJ-20142 following oral administrations of 
10 mg/kg of tepoxalin in fasting and fed horses (n = 6 except where indicated). 
 
r2, correlation coefficient; λz, terminal phase rate constant; T1/2λz, terminal half-life; Tmax, 
time of peak; Cmax, peak plasma concentration; VzF, volume of distribution based on the 
terminal phase; CL, clearance of the terminal phase; AUClast, area under the plasma 
concentration–time curve; AUMClast, area under the first moment curve; MRTlast, mean 
resident time. Data originated from four1 and five2 horses. Nd = not detected.  
a Value significantly different (P < 0.05) between fasting and fed groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Mean ± SEM (n = 3) of percentage (%) inhibition of thromboxane B2 (TXB2), prostaglandin  
E2 (PGE2) and leukotriene B4 (LTB4) in fasting/fed equine whole blood before and after 
single oral administration of tepoxalin (10 mg/kg).  
 
Repeated-measures one-way ANOVA revealed significant differences in % inhibition of 
TXB2 of fasting (a vs. b, P < 0.05) and fed horses (a vs. b, P < 0.001), and LTB4 of fasting 
horses (a vs. b, P < 0.05). No statistical differences were detected between fasting and fed 
groups. 
